141 related articles for article (PubMed ID: 23390553)
1. Effects of the endpoint adjudication process on the results of a randomised controlled trial: the ADVANCE trial.
Hata J; Arima H; Zoungas S; Fulcher G; Pollock C; Adams M; Watson J; Joshi R; Kengne AP; Ninomiya T; Anderson C; Woodward M; Patel A; Mancia G; Poulter N; MacMahon S; Chalmers J; Neal B;
PLoS One; 2013; 8(2):e55807. PubMed ID: 23390553
[TBL] [Abstract][Full Text] [Related]
2. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
Patel A; ; MacMahon S; Chalmers J; Neal B; Woodward M; Billot L; Harrap S; Poulter N; Marre M; Cooper M; Glasziou P; Grobbee DE; Hamet P; Heller S; Liu LS; Mancia G; Mogensen CE; Pan CY; Rodgers A; Williams B
Lancet; 2007 Sep; 370(9590):829-40. PubMed ID: 17765963
[TBL] [Abstract][Full Text] [Related]
3. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial.
Beulens JW; Patel A; Vingerling JR; Cruickshank JK; Hughes AD; Stanton A; Lu J; McG Thom SA; Grobbee DE; Stolk RP; ;
Diabetologia; 2009 Oct; 52(10):2027-36. PubMed ID: 19633827
[TBL] [Abstract][Full Text] [Related]
4. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
Hata J; Arima H; Rothwell PM; Woodward M; Zoungas S; Anderson C; Patel A; Neal B; Glasziou P; Hamet P; Mancia G; Poulter N; Williams B; Macmahon S; Chalmers J;
Circulation; 2013 Sep; 128(12):1325-34. PubMed ID: 23926207
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
6. ADVANCE: action in diabetes and vascular disease.
Patel A; Chalmers J; Poulter N
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S27-32. PubMed ID: 16075030
[TBL] [Abstract][Full Text] [Related]
7. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE.
Poulter NR
J Hypertens Suppl; 2009 May; 27(1):S3-8. PubMed ID: 19483505
[TBL] [Abstract][Full Text] [Related]
8. New insights from ADVANCE.
Chalmers J; Kengne AP; Joshi R; Perkovic V; Patel A
J Hypertens Suppl; 2007 Jun; 25(1):S23-30. PubMed ID: 17579315
[TBL] [Abstract][Full Text] [Related]
9. Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment.
Zhou J; Xu B; He F; Shu Y; Chen X; Liu Z; Sun B; Zhang W
Cardiovasc Diabetol; 2024 May; 23(1):166. PubMed ID: 38730425
[TBL] [Abstract][Full Text] [Related]
10. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
Ismail-Beigi F; Craven TE; O'Connor PJ; Karl D; Calles-Escandon J; Hramiak I; Genuth S; Cushman WC; Gerstein HC; Probstfield JL; Katz L; Schubart U;
Kidney Int; 2012 Mar; 81(6):586-94. PubMed ID: 22166848
[TBL] [Abstract][Full Text] [Related]
11. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation.
J Hypertens Suppl; 2001 Nov; 19(4):S21-8. PubMed ID: 11848259
[TBL] [Abstract][Full Text] [Related]
13. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
[TBL] [Abstract][Full Text] [Related]
14. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
[TBL] [Abstract][Full Text] [Related]
15. Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS).
Ninomiya T; Donnan G; Anderson N; Bladin C; Chambers B; Gordon G; Sharpe N; Chalmers J; Woodward M; Neal B;
Stroke; 2009 Jun; 40(6):2111-5. PubMed ID: 19359647
[TBL] [Abstract][Full Text] [Related]
16. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
Dormandy JA; Charbonnel B; Eckland DJ; Erdmann E; Massi-Benedetti M; Moules IK; Skene AM; Tan MH; Lefèbvre PJ; Murray GD; Standl E; Wilcox RG; Wilhelmsen L; Betteridge J; Birkeland K; Golay A; Heine RJ; Korányi L; Laakso M; Mokán M; Norkus A; Pirags V; Podar T; Scheen A; Scherbaum W; Schernthaner G; Schmitz O; Skrha J; Smith U; Taton J;
Lancet; 2005 Oct; 366(9493):1279-89. PubMed ID: 16214598
[TBL] [Abstract][Full Text] [Related]
17. Effects of fasting blood glucose, diabetes treatment, blood pressure and anti-hypertension treatment on cardiovascular disease incidence: a 30-year follow-up study of 740 incident patients with Type 2 diabetes.
Jansson SP; Andersson DK; Svärdsudd K
Diabet Med; 2013 Mar; 30(3):349-57. PubMed ID: 23278364
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy.
Weber MA; Bloch M; Bakris GL; Weir MR; Zappe DH; Dahlof B; Velazquez EJ; Pitt B; Basile JN; Jamerson K; Hua TA
J Clin Hypertens (Greenwich); 2016 Apr; 18(4):299-307. PubMed ID: 27060568
[TBL] [Abstract][Full Text] [Related]
19. Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
ADVANCE Management Committee
Diabetologia; 2001 Sep; 44(9):1118-20. PubMed ID: 11596665
[TBL] [Abstract][Full Text] [Related]
20. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
